Descriptive Comparison of the Efficacy and Safety of OnabotulinumtoxinA for Headache Prophylaxis in Adult Chronic Migraine Patients from Two Long-term, Multicenter Studies: COMPEL vs. PREEMPT

被引：0
|
作者：
Aurora, S. [1 ]
Stark, R. [2 ,3 ]
Reppine, A. [4 ]
Adams, Manack A. [4 ]
Blumenfeld, A.
机构：
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[2] Monash Univ, Clayton, Vic 3800, Australia
[3] Alfred Hosp, Melbourne, Vic, Australia
[4] Allergan Pharmaceut Inc, Irvine, CA USA
来源：
HEADACHE | 2015年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PF18
引用
收藏
页码：142 / 142
页数：1
相关论文
共 50 条
  • [1] Descriptive comparison of the efficacy and safety of onabotulinumtoxina for headache prophylaxis in adult chronic migraine patients from two long-term, multicenter studies: compel vs. Preempt
    Aurora, S.
    Stark, R.
    Reppine, A.
    Adams, A. Manack
    Blumenfeld, A.
    CEPHALALGIA, 2015, 35 : 47 - 47
  • [2] Efficacy and safety of onabotulinumtoxinA for the prophylaxis of headaches in adult chronic migraine patients: an interim analysis of the prospective, long-term, multicenter, open-label study, COMPEL
    Blumenfeld, A.
    Stark, R.
    Reppine, A.
    Halstead, M.
    Holdbrook, F.
    Adams, A. Manack
    Aurora, S.
    JOURNAL OF PAIN, 2015, 16 (04): : S92 - S92
  • [3] Rationale for Study and Design of COMPEL: An Open-Label, Multicenter Study of the Long-Term Efficacy, Safety, and Tolerability of OnabotulinumtoxinA for Headache Prophylaxis in Adults with Chronic Migraine
    Blumenfeld, A. M.
    Aurora, S. K.
    Laranjo, K.
    Varon, S. F.
    Papapetropoulos, S.
    HEADACHE, 2012, 52 (05): : 881 - 881
  • [4] Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
    Blumenfeld, Andrew M.
    Stark, Richard J.
    Freeman, Marshall C.
    Orejudos, Amelia
    Adams, Aubrey Manack
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [5] Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
    Andrew M. Blumenfeld
    Richard J. Stark
    Marshall C. Freeman
    Amelia Orejudos
    Aubrey Manack Adams
    The Journal of Headache and Pain, 2018, 19
  • [6] Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine
    Andrew M. Blumenfeld
    Sheena K. Aurora
    Karen Laranjo
    Spyros Papapetropoulos
    BMC Neurology, 15
  • [7] Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine
    Blumenfeld, Andrew M.
    Aurora, Sheena K.
    Laranjo, Karen
    Papapetropoulos, Spyros
    BMC NEUROLOGY, 2015, 15
  • [8] The Long-Term Efficacy and Safety of OnabotulinumtoxinA for the Prevention of Chronic Migraine in Patients with Medication Overuse: Results of the COMPEL Study
    Tepper, S. J.
    Wilson, M.
    Orejudos, A.
    Adams, Manack A.
    Blumenfeld, A.
    HEADACHE, 2018, 58 : 93 - 94
  • [9] The long-term efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine in patients with medication overuse: results of the COMPEL study
    Tepper, S.
    Wilson, M. -C.
    Orejudos, A.
    Adams, A. Manack
    Blumenfeld, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 78 - 78
  • [10] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study
    Winner, Paul K.
    Blumenfeld, Andrew M.
    Eross, Eric J.
    Orejudos, Amelia C.
    Mirjah, Debbie L.
    Adams, Aubrey Manack
    Brin, Mitchell F.
    DRUG SAFETY, 2019, 42 (08) : 1013 - 1024
12345